Abstract
Pyrogallol reversibly and noncompetitively inhibits the activity of the hepatitis C RNA-dependent RNA polymerase. Based on molecular modeling of the inhibitor binding in the active site of the enzyme, the inhibition was suggested to be realized via chelation of two magnesium cations involved in the catalysis at the stage of the phosphoryl residue transfer. The proposed model allowed us to purposefully synthesize new derivatives with higher inhibitory capacity.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminobutyrates / pharmacology
-
Binding Sites
-
Chelating Agents / pharmacology
-
Hepacivirus / enzymology*
-
Magnesium / chemistry
-
Models, Molecular
-
Phenylbutyrates
-
Pyrogallol / analogs & derivatives*
-
Pyrogallol / pharmacology*
-
RNA-Dependent RNA Polymerase / antagonists & inhibitors*
Substances
-
2,4-dioxo-4-phenylbutanoic acid
-
Aminobutyrates
-
Chelating Agents
-
Phenylbutyrates
-
Pyrogallol
-
RNA-Dependent RNA Polymerase
-
Magnesium